Skip to main content
. 2022 Aug 2;14(8):1617. doi: 10.3390/pharmaceutics14081617
3D three dimensional
ACDA acid citrate dextrose solution
ADSC Adipose-derived mesenchymal stem cells
Ang 1 angiopoietin-1
BCT blood cell therapy
βIgH3 factor-β-induced protein Ig-H3
CE European conformity
CEO chief executive officer
EC endothelial cells
FBA fibrin bead assay
FBS fetal bovine serum
GMP good manufacturing practices
HA hyaluronic acid
HGF hepatocyte growth factor
HUVEC human umbilical vein endothelial cells
IGFBP7 insulin-like growth factor binding protein 7
LP-PRP leukocyte poor PRP
LR-PRP leukocyte rich PRP
NHDF normal human dermal fibroblasts
MDD medical device directive
MDR medical device regulation
MDSAP medical device single audit program
MNC mononuclear cells
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
OA osteoarthritis
Ph. Eur European pharmacopeia
PPP platelet poor plasma
PRP platelet-rich plasma
PRP-HA platelet-rich plasma combined with hyaluronic acid
PL platelet lysates
SMA smooth muscle actin
SPARC secreted protein acidic and cysteine-rich
TGF-α transforming growth factor alpha
USP US pharmacopeia